Concepedia

Tirrell Johnson

TJ

Statistics

Publications

4

Citations

379

H-Index

4

Active since

2011

Affiliations

University of California, Los Angeles(Current)

Tirrell Johnson is an author at University of California, Los Angeles specializing in oncology, chemotherapy, and medicine.

Publications per year

2011–2024

4

Publications

4

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub et al. · Clinical Cancer Research · 2017 · 159 citations · Full text

Medicine, Oncology, Pharmacology +17

Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Neal Ready, Ritesh Rathore, Tirrell Johnson et al. · American Journal of Clinical Oncology · 2011 · 21 citations

Medicine, Oncology, Radiation Oncology +13

Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).

Jonathan W. Goldman, Amy L. Cummings, Melody Mendenhall et al. · Journal of Clinical Oncology · 2022 · 17 citations

Medicine, Oncology, Pharmacology +13

1–4 of 4